IMUX
Immunic, Inc.NASDAQHealthcare$1.16+0.87%ClosedMarket Cap: $114.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-272.97
P/S
0.00
EV/EBITDA
-1.02
DCF Value
$0.01
FCF Yield
-74.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1197.8%
ROA
-404.0%
ROIC
1693.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-23.3M | $-19.3M | $-0.04 | — |
| FY 2025 | $0.00 | -Infinity% | $-103.2M | $-97.2M | $-0.62 | — |
| Q3 2025 | $0.00 | NaN% | $-26.0M | $-25.6M | $-0.13 | — |
| Q2 2025 | $0.00 | NaN% | $-27.1M | $-26.8M | $-0.20 | — |
| Q1 2025 | $0.00 | NaN% | $-26.8M | $-25.5M | $-0.25 | — |
| Q4 2024 | $0.00 | -Infinity% | $-25.6M | $-25.2M | $-0.28 | — |
| FY 2024 | $0.00 | NaN% | $-98.1M | $-100.5M | $-1.00 | — |
| Q3 2024 | $0.00 | NaN% | $-25.7M | $-24.4M | $-0.24 | — |
| Q2 2024 | $0.00 | -Infinity% | $-22.8M | $-21.4M | $-0.21 | — |
| Q1 2024 | $0.00 | -Infinity% | $-23.9M | $-29.6M | $-0.30 | — |
| Q4 2023 | $0.00 | -Infinity% | $-23.4M | $-21.6M | $-0.48 | — |
| FY 2023 | $0.00 | NaN% | $-99.2M | $-93.6M | $-2.11 | — |